Chen Bihua — Form SCHEDULE 13D/A
Filed July 6, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 22/100
What the filing says
On July 1, 2026, Helix Holdings II LLC (the Sponsor of BridgeBio Oncology Therapeutics, Inc.) distributed 4,528,186 lock-up shares to three Cormorant funds: 2,692,459 to Fund III, 1,704,862 to Fund V, and 130,865 to Global Healthcare Master Fund. All recipients executed a joinder agreement on July 6, 2026, agreeing to be bound by the same transfer restrictions as the original Lock-Up Agreement (dated August 11, 2025). No dollar amounts or percentage holdings disclosed.
Why this rating
Administrative restructuring of existing lock-up shares among related entities; no new issuance, sale, or change in control. Standard sponsor liquidity distribution.
See more from July 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.